Racing with Merck, Pfizer wins FDA 'breakthrough' tag for 20-valent pneumococcal vaccine

Pfizer sign
Pfizer secured an FDA Breakthrough Therapy Designation for its 20-valent pneumococcal vaccine candidate. (Tracy Staton)

Pfizer and Merck are racing to the market with their next-gen pneumococcal candidates, and on Thursday, Pfizer's program got a major boost. The FDA granted the company's 20-valent vaccine its Breakthrough Therapy Designation in adults as the drugmaker prepares for late-stage testing.

With the breakthrough designation, Pfizer's program gets the perks of a FDA Fast Track designation, potentially including more frequent communications with the agency. The vaccine could win accelerated approval and priority review under certain circumstances. The breakthrough designation is based on phase 2 data, and Pfizer plans to advance to phase 3 “in a few months," the company said.

Meanwhile, Merck is already in phase 3 testing with its 15-valent program, dubbed V114.

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

At a healthcare conference last week, Pfizer CFO Frank D’Amelio said the company is “all in” on advancing its candidate. After Pfizer closed its internal neuroscience outfit earlier this year, the company shifted resources to accelerate the vaccine’s development, he said.

The stakes are high. Pfizer’s Prevnar 13 already pulls in billions of dollars annually, and both drugmakers want to own as much of the market as possible. Merck entered phase 3 testing in April.

RELATED: Pfizer 'all in' on advancing next-generation pneumococcal vaccine candidate: CFO

Still, Pfizer executives have said they believe the drugmaker can launch its vaccine at a “competitive” time frame to Merck. If Pfizer's launch timing is competitive, D’Amelio said extra protection offered by the shot and the strength of the Prevnar franchise should allow the company to hold market share and keep growing its business. 

Merck R&D chief Roger Perlmutter, M.D., Ph.D., for his part, has said he envisions a need for multiple pneumococcal vaccines in the future. In one phase 3 study, Merck is testing its V114 in a head-to-head against Pfizer's Prevnar 13.

RELATED: Merck pits its pneumococcal shot against Pfizer's mammoth Prevnar in head-to-head phase 3 

Merck and Pfizer are two of the largest vaccine companies globally, generating $6.5 billion and $6 billion in the field last year, respectively.  

Suggested Articles

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.

A group of drugmakers and others say some federal policies to fight COVID-19 are it making more expensive and harder to get some drugs.